Showing results (31-40 of 689) with videos related to

Sort By:
Pageof 69
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 19, 2003
Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitusJuris J Meier, Baptist Gallwitz, Michael A Nauck
Diabetes|November 25, 2004
Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetesMichael A Nauck, Birgit Baller, Juris J Meier
Trends in Endocrinology and Metabolism: TEM|February 22, 2018
Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual PatternsSoo Lim, Kyoung Min Kim, Michael A Nauck
Deutsches Arzteblatt International|November 6, 2009
Self-monitoring of blood glucose in diabetes mellitus: arguments for an individualized approachMichael A Nauck, Andrea El-Ouaghlidi, Irfan Vardarli
Nature Metabolism|June 12, 2023
Gut hormone co-agonists for the treatment of obesity: from bench to bedsideRuben Nogueiras, Michael A Nauck, Matthias H Tschöp
Endocrinology|November 21, 2024
Physiology and Pharmacology of Effects of GLP-1-based Therapies on Gastric, Biliary and Intestinal MotilityRyan J Jalleh, Chinmay S Marathe, Christopher K Rayner, et al.
The Journal of Clinical Endocrinology and Metabolism|October 17, 2024
Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and TirzepatideRyan J Jalleh, Mark P Plummer, Chinmay S Marathe, et al.
The Journal of Clinical Endocrinology and Metabolism|August 9, 2019
Longitudinal Changes in Fasting and Glucose-Stimulated GLP-1 and GIP in Healthy Older SubjectsHung Pham, Chinmay S Marathe, Liza K Phillips, et al.
Pageof 69